cropped color_logo_with_background.png

Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics

Study Purpose

The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages 18 Years - 70 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. >=18 years old. 2. Primary Glioblastoma is newly diagnosed and confirmed histologically. 3. Patient is expected to be treated with temozolomide and followed up routinely at the study site. 4. Willing to sign the informed consent.

Exclusion Criteria:

1. Currently enrolled in any other clinical study. 2. History of any other malignancies. 3. Refusal to give consent. 4. No available tumor tissue for IDH analysis.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02047058
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Nanfang Hospital, Southern Medical University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Songtao Qi, Doctor
Principal Investigator Affiliation Nanfang Glioma centre, Guangzhou, China
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Unknown status
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Glioblastoma, Malignant Glioma
Additional Details

The unique markers of Qcell were screened using the method of genomics and.proteomics, then these markers will be qualitatively and quantitatively evaluated in.glioblastoma patients by comparing their relationship with overrall.survival/progression-free survival and treatment response.

Arms & Interventions

Arms

: high-risk

high-risk is determined by the evaluation of the biomarkers of Q cell.

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Nanfang Glioma Centre, Guangzhou, Guangdong, China

Status

Address

Nanfang Glioma Centre

Guangzhou, Guangdong, 510515